Eterna Therapeutics
ERNA
9 hedge funds and large institutions have $5.36M invested in Eterna Therapeutics in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and 0 closing their positions.
13% more funds holding
Funds holding: 8 → 9 (+1)
14% less capital invested
Capital invested by funds: $6.21M → $5.36M (-$854K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NSIM
North Star Investment Management
Chicago,
Illinois
|
+$432K |
| 2 |
Renaissance Technologies
New York
|
+$108K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
1
AWM Investment Company
New York
| $2.2M | – | – | – |
|
|
NSIM
2
North Star Investment Management
Chicago,
Illinois
| $1.68M | +$432K | +4 | +31% |
|
|
EAM
3
Eagle Asset Management
St Petersburg,
Florida
| $613K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $283K | +$108K | +1 | +50% |
|
5
Geode Capital Management
Boston,
Massachusetts
| $144K | – | – | – |
|
|
CA
6
Callahan Advisors
Houston,
Texas
| $128K | – | – | – |
|
7
Vanguard Group
Malvern,
Pennsylvania
| $120K | – | – | – |
|
8
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $102K | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $57K | +$108K | +1 | New |
|
10
BlackRock
New York
| $20K | – | – | – |
|
11
Barclays
London,
United Kingdom
| $1K | – | – | – |
|
|
LTFS
12
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
13
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1K | – | – | – |
|
|
14
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$9K | – | – |
|
ERNA Hedge Fund Activity: Q2 2017 in Review
9 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q2 2017, worth a combined $5.36M — down 14% from $6.21M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ERNA positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was North Star Investment Management, adding an estimated $432K. The largest seller was Deutsche Bank, cutting an estimated $9K.
- 9 institutional investors held Eterna Therapeutics (ERNA) as of Q2 2017, up from 8 in Q1 2017.
- Funds reported $5.36M of Eterna Therapeutics stock for Q2 2017, down 14% quarter-over-quarter.
- 1 fund opened new Eterna Therapeutics positions in Q2 2017 and 0 closed out, a net change of +1 holder.
- The largest Eterna Therapeutics buyer in Q2 2017 was North Star Investment Management, an estimated $432K added.
- The largest Eterna Therapeutics seller in Q2 2017 was Deutsche Bank, an estimated $9K sold.
Based on aggregated 13F filings for Q2 2017.